Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

Media Hub

  1. Home
  2. Media

Latest Press Releases

  • Number of shares and voting rights of Innate Pharma as of November 27, 2025

    November 28, 2025
  • Innate Pharma to present at Jefferies Global Healthcare Conference

    November 17, 2025
  • Innate Pharma reports Third Quarter 2025 business update and financial results

    November 13, 2025

Selected media

  • Trois questions à Jonathan Dickinson, Président du Directoire d'Innate Pharma

    Mon, 12/09/2024 - 00:00
    • Read more about Trois questions à Jonathan Dickinson, Président du Directoire d'Innate Pharma
  • ANKET: Our NK cell engager platform

    Thu, 06/10/2021 - 07:00

    Click here to learn more about ANKETTM

    • Read more about ANKET: Our NK cell engager platform
  • Interview of Eric Vivier “The new generation of NK cell therapies”

    Fri, 02/05/2021 - 08:00

    Interview Eric Vivier "The new generation of NK cell therapies"

    • Read more about Interview of Eric Vivier “The new generation of NK cell therapies”

Tweets by InnatePharma

Media and Investor Relations contact details

Stéphanie Cornen

communication@innate-pharma.com

   

 

 

 

Footer

  • Contact
  • Location
  • Site map
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

 +33 (0)4 30 30 30 30

 Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers